Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma (IPi-504-01)
Tracking Information | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Received Date ICMJE | June 6, 2005 | ||||||||||||||||
Last Updated Date | May 15, 2008 | ||||||||||||||||
Start Date ICMJE | June 2005 | ||||||||||||||||
Primary Completion Date | March 2007 (final data collection date for primary outcome measure) | ||||||||||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||||||||||
Original Primary Outcome Measures ICMJE |
|
||||||||||||||||
Change History | Complete list of historical versions of study NCT00113204 on ClinicalTrials.gov Archive Site | ||||||||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||||||||
Original Secondary Outcome Measures ICMJE |
|
||||||||||||||||
Current Other Outcome Measures ICMJE | |||||||||||||||||
Original Other Outcome Measures ICMJE | |||||||||||||||||
Descriptive Information | |||||||||||||||||
Brief Title ICMJE | Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma | ||||||||||||||||
Official Title ICMJE | A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Relapsed, and Relapsed Refractory Multiple Myeloma | ||||||||||||||||
Brief Summary | This is a phase 1 clinical trial to find the safe, maximum tolerated dose of IPI-504 in patients with relapsed and/or relapsed, refractory multiple myeloma. This study will examine how IPI-504 is absorbed, distributed, metabolized, and eliminated by the body. The study will also evaluate potential anti-tumor activity of IPI-504. |
||||||||||||||||
Detailed Description | IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90), an emerging and recently identified target for cancer therapy. Hsp90 is a protein chaperone that plays a central role in regulating protein homeostasis. Hsp90 regulates the stability of key proteins (called "client proteins") and keeps them in the appropriate three dimensional shape so they can perform their cellular functions. In addition, many of the proteins stabilized by Hsp90 are oncoproteins and cell-signaling proteins important in cancer cell proliferation and cancer cell survival. Thus Hsp90, a single molecular target that is a central integrator of multiple pathways important to cancer, is an ideal novel target for oncologic therapy. Selective inhibition of Hsp90 will affect multiple downstream mechanisms to disrupt tumor growth and selectively kill cancer cells. The anti-neoplastic effects of Hsp90 inhibition have been demonstrated both in vitro and in vivo for a variety of different hematologic and solid tumors including multiple myeloma. |
||||||||||||||||
Study Type ICMJE | Interventional | ||||||||||||||||
Study Phase | Phase 1 | ||||||||||||||||
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
||||||||||||||||
Condition ICMJE | Multiple Myeloma | ||||||||||||||||
Intervention ICMJE | Drug: IPI-504
Other Name: IPI-504 |
||||||||||||||||
Study Arm (s) | |||||||||||||||||
Publications * |
|
||||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||
Recruitment Information | |||||||||||||||||
Recruitment Status ICMJE | Completed | ||||||||||||||||
Enrollment ICMJE | 18 | ||||||||||||||||
Completion Date | March 2007 | ||||||||||||||||
Primary Completion Date | March 2007 (final data collection date for primary outcome measure) | ||||||||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||||
Gender | Both | ||||||||||||||||
Ages | 18 Years and older | ||||||||||||||||
Accepts Healthy Volunteers | No | ||||||||||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||||||||
Location Countries ICMJE | United States | ||||||||||||||||
Administrative Information | |||||||||||||||||
NCT Number ICMJE | NCT00113204 | ||||||||||||||||
Other Study ID Numbers ICMJE | IPI-504-01 | ||||||||||||||||
Has Data Monitoring Committee | No | ||||||||||||||||
Responsible Party | |||||||||||||||||
Study Sponsor ICMJE | Infinity Pharmaceuticals, Inc. | ||||||||||||||||
Collaborators ICMJE | |||||||||||||||||
Investigators ICMJE |
|
||||||||||||||||
Information Provided By | Infinity Pharmaceuticals, Inc. | ||||||||||||||||
Verification Date | May 2008 | ||||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |